Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
Not yet accepting
IRAK
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
- IRAK 4 Inhibitor
- IRAK 1 Inhibitor
- Phase 1/2
- Has results
Accepting patients
RALLY-MF
RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
- Monoclonal Antibody
- Hemojuvelin (HJV)
- Monotherapy
- Randomization
- Phase 1/2
- Has results
Accepting patients
Safety Study of Cord Blood Units
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
DEC-C Post-Transplant
A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- Cytidine Deaminase Inhibitor
- Post-Allogeneic Stem Cell Transplant
- Phase 1/2
Accepting patients
Interferon-γ With Donor Leukocyte Infusion
A Phase 2 Trial of Interferon-γ (IFN-γ) in Combination With Donor Leukocyte Infusion (DLI) to Treat Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
- Immunotherapy
- Donor Lymphocyte Infusion (DLI)
- Phase 2
Accepting patients
Atorvastatin vs. Rosuvastatin
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
- Statin
- Phase 2
Accepting patients
CROSSCHECK-001
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias (CROSSCHECK-001)
- T Cell Engager (TCE)
- Cathepsin G (CTSG)
- Phase 1
Accepting patients
AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
- Monoclonal Antibody
- CD47
- Placebo
- Closed Label (Masked)
- Randomization
- Phase 2
Accepting patients
Imetelstat Combination Therapy
A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
- Telomerase Inhibitor
- Phase 1
Accepting patients
Eganelisib
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- PI3K Inhibitor
- Randomization
- Phase 1